Evaluation of the Biop Colposcopy System's Safety and Performance (Accuracy of Its Registration Procedure)
Primary Purpose
Cervical Cancer Screening
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Biop Colposcopy System
Sponsored by
About this trial
This is an interventional screening trial for Cervical Cancer Screening
Eligibility Criteria
Inclusion Criteria:
- Females, ages 22 to 65 years old
- Referred for colposcopy, following abnormal cervical cytology
- Subject provides signed informed consent
Exclusion Criteria:
- Currently pregnant or nursing
- Currently menstruating
- Currently has intrauterine device (IUD)
- Diagnosed with diseases that may influence the color of the tissue, e.g., hepatitis, polycytemia vera.
- Diagnosed with pathologies that affect blood coagulation, the immune system or undergoing any treatment that interfere with coagulation or the immune system
- HIV-positive status
- Psychological instability, inappropriate attitude or motivation
- Use of any additional experimental drug or device or participation in another clinical study within the past 30 days
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Biop Coplposcopy System
Arm Description
Biop Colposcopy system procedure
Outcomes
Primary Outcome Measures
Performance
The primary performance endpoint is the image registration success. Image registration success is defined by the registration error (distance between corresponding control points following registration). Average image registration error should be less than or equal to (≤) to 2mm.
frequency and incidence of all Adverse Events
Safety endpoints include frequency and incidence of all Adverse Events (AE) and Serious Adverse Events (SAE) related and unrelated to the device use.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03750214
Brief Title
Evaluation of the Biop Colposcopy System's Safety and Performance (Accuracy of Its Registration Procedure)
Official Title
Bio Colposcopy System CIP: Evaluation of the Biop Colposcopy System's Safety and Performance (Accuracy of Its Registration Procedure)
Study Type
Interventional
2. Study Status
Record Verification Date
January 2020
Overall Recruitment Status
Unknown status
Study Start Date
May 2020 (Anticipated)
Primary Completion Date
November 2020 (Anticipated)
Study Completion Date
December 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
BIOP Medical
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a multi-center, prospective, non-randomized, confirmatory study to evaluate the safety and performance of the Biop Digital Colposcope and the accuracy of the image registration procedure between the Biop Digital Colposcope unit and the Biop Micro Colposcope probe unit.
Detailed Description
This is a multi-center, prospective, non-randomized, confirmatory study to evaluate the safety and performance of the Biop Digital Colposcope and the accuracy of the image registration procedure between the Biop Digital Colposcope unit and the Biop Micro Colposcope probe unit.
The Biop Digital Colposcope is intended for magnified viewing of the tissues of the vagina, cervix and external genitalia in order to assist doctors in diagnosing abnormalities such as lesions or cancer, and selecting areas for biopsy. The images from the digital colposcope are to be viewed on a color display. The digital colposcope is intended for use in hospitals, clinics, and doctor's offices.
The Biop Micro Colposcope probe unit is an imaging tool intended to be placed in the vagina for acquisition of images of the cervix. It is intended as an adjunct to the Biop Digital Colposcope. It should NOT be used as a substitute for a thorough colposcopic evaluation. The Biop Micro Colposcope Probe unit is not intended for use on the vulva and vagina.
It is anticipated that it will take approximately 3 months to complete active enrollment. Study duration for each subject is 1-2 days, including screening, enrolment and procedure. The study will be completed when the final study subject has completed the procedure.
Performance - to confirm that average image registration error is less than or equal to (≤) 2mm.
Safety - to evaluate the safety of the Biop Digital Colposcope in women undergoing cervical colposcopy procedures.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cervical Cancer Screening
7. Study Design
Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
26 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Biop Coplposcopy System
Arm Type
Experimental
Arm Description
Biop Colposcopy system procedure
Intervention Type
Device
Intervention Name(s)
Biop Colposcopy System
Intervention Description
The procedure stages:
Scanning of the cervix - the cervix is scanned using the micro colposcope probe unit, to produce a total of 51 micro-images and one macro image from the panoramic camera.
Colposcopy exam - during the standard colposcopy exam, the doctor acquires a panoramic image of the cervix with the digital colposcope.
A questionnaire completed by the subject after the Biop procedure, with regards to any unusual sensations or events experienced during the procedure.
A questionnaire completed by the user after the Biop procedure, with regards to system usage
Image Registration analysis
Primary Outcome Measure Information:
Title
Performance
Description
The primary performance endpoint is the image registration success. Image registration success is defined by the registration error (distance between corresponding control points following registration). Average image registration error should be less than or equal to (≤) to 2mm.
Time Frame
procedure day ± 1 day
Title
frequency and incidence of all Adverse Events
Description
Safety endpoints include frequency and incidence of all Adverse Events (AE) and Serious Adverse Events (SAE) related and unrelated to the device use.
Time Frame
procedure day ± 1 day
Other Pre-specified Outcome Measures:
Title
Exploratory Endpoint
Description
Subject's comfort - as measured by a questionnaire
Time Frame
procedure day ± 1 day
10. Eligibility
Sex
Female
Gender Based
Yes
Gender Eligibility Description
Females, ages 22 to 65 years old
Minimum Age & Unit of Time
22 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Females, ages 22 to 65 years old
Referred for colposcopy, following abnormal cervical cytology
Subject provides signed informed consent
Exclusion Criteria:
Currently pregnant or nursing
Currently menstruating
Currently has intrauterine device (IUD)
Diagnosed with diseases that may influence the color of the tissue, e.g., hepatitis, polycytemia vera.
Diagnosed with pathologies that affect blood coagulation, the immune system or undergoing any treatment that interfere with coagulation or the immune system
HIV-positive status
Psychological instability, inappropriate attitude or motivation
Use of any additional experimental drug or device or participation in another clinical study within the past 30 days
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dana Raveh Arbel
Phone
972528591891
Email
dana@biopmedical.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ram Eitan, Md.
Organizational Affiliation
RMC Israel
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Evaluation of the Biop Colposcopy System's Safety and Performance (Accuracy of Its Registration Procedure)
We'll reach out to this number within 24 hrs